| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8525112 | Biomedicine & Pharmacotherapy | 2018 | 18 Pages |
Abstract
Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Dinesh Kumar Chellappan, Kun Hooi Leng, Lee Jia Jia, Nur Amirah Binti Abdul Aziz, Wong Chun Hoong, Yap Cheng Qian, Fam Yi Ling, Gwee Sing Wei, Tiong Ying, Jestin Chellian, Gaurav Gupta, Kamal Dua,